Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
bile acid metabolism
biomarkers
cancer prevention
hepatocellular carcinoma
obesity
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 04 2022
15 04 2022
Historique:
revised:
04
10
2021
received:
03
08
2021
accepted:
13
10
2021
pubmed:
30
11
2021
medline:
25
2
2022
entrez:
29
11
2021
Statut:
ppublish
Résumé
Bile acids (BAs) play different roles in cancer development. Some are carcinogenic and BA signaling is also involved in various metabolic, inflammatory and immune-related processes. The liver is the primary site of BA synthesis. Liver dysfunction and microbiome compositional changes, such as during hepatocellular carcinoma (HCC) development, may modulate BA metabolism increasing concentration of carcinogenic BAs. Observations from prospective cohorts are sparse. We conducted a study (233 HCC case-control pairs) nested within a large observational prospective cohort with blood samples taken at recruitment when healthy with follow-up over time for later cancer development. A targeted metabolomics method was used to quantify 17 BAs (primary/secondary/tertiary; conjugated/unconjugated) in prediagnostic plasma. Odd ratios (OR) for HCC risk associations were calculated by multivariable conditional logistic regression models. Positive HCC risk associations were observed for the molar sum of all BAs (OR
Substances chimiques
Bile Acids and Salts
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1255-1268Subventions
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A29017
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Informations de copyright
© 2021 UICC.
Références
Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep. 2019;6:104-111.
Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15:14-22.
Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132:645-657.
Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr. 2018;18:71-87.
Li T, Chiang JY. Bile acids as metabolic regulators. Curr Opin Gastroenterol. 2015;31:159-165.
Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res. 2005;589:47-65.
Phelan JP, Reen FJ, Caparros-Martin JA, O'Connor R, O'Gara F. Rethinking the bile acid/gut microbiome axis in cancer. Oncotarget. 2017;8:115736-115747.
Wu L, Feng J, Li J, et al. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother. 2021;133:111036.
Ramírez-Pérez O, Cruz-Ramón V, Chinchilla-López P, Méndez-Sánchez N. The role of the gut microbiota in bile acid metabolism. Ann Hepatol. 2017;16:S15-S20.
Trefflich I, Marschall HU, Giuseppe RD, et al. Associations between dietary patterns and bile acids-results from a cross-sectional study in vegans and omnivores. Nutrients. 2019;12:47-61.
Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152:1679-94.e3.
Beyoglu D, Idle JR. The metabolomic window into hepatobiliary disease. J Hepatol. 2013;59:842-858.
Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15:111-128.
Gottlieb A, Canbay A. Why bile acids are so important in nonalcoholic fatty liver disease (NAFLD) progression. Cell. 2019;8:1358-1373.
Ciocan D, Voican CS, Wrzosek L, et al. Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis. Aliment Pharmacol Ther. 2018;48:961-974.
Puri P, Daita K, Joyce A, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology (Baltimore, MD). 2018;67:534-548.
Di Ciaula A, Wang DQ, Molina-Molina E, et al. Bile acids and cancer: direct and environmental-dependent effects. Ann Hepatol. 2017;16:S87-S105.
Kettner NM, Voicu H, Finegold MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell. 2016;30:909-924.
Liu N, Feng J, Lv Y, et al. Role of bile acids in the diagnosis and progression of liver cirrhosis: a prospective observational study. Exp Ther Med. 2019;18:4058-4066.
Stepien M, Keski-Rahkonen P, Kiss A, et al. Metabolic perturbations prior to hepatocellular carcinoma diagnosis: findings from a prospective observational cohort study. Int J Cancer. 2020;148:609-625. https://onlinelibrary.wiley.com/doi/10.1002/ijc.33236
Loftfield E, Rothwell JA, Sinha R, et al. Prospective investigation of serum metabolites, coffee drinking, liver cancer incidence, and liver disease mortality. J Natl Cancer Inst. 2020;112:286-294.
Petrick JL, Florio AA, Koshiol J, et al. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer. 2020;147:2743-2753.
Thomas CE, Luu HN, Wang R, et al. Association between prediagnostic serum bile acids and hepatocellular carcinoma: the Singapore Chinese health study. Cancers. 2021;2648-2663.
Jee SH, Kim M, Kim M, et al. Metabolomics profiles of hepatocellular carcinoma in a Korean prospective cohort: the Korean Cancer Prevention Study-II. Cancer Prev Res (Philadelphia, Pa). 2018;11:303-312.
Zhang W, Zhou L, Yin P, et al. A weighted relative difference accumulation algorithm for dynamic metabolomics data: long-term elevated bile acids are risk factors for hepatocellular carcinoma. Sci Rep. 2015;5:8984.
Wang H, Shang X, Wan X, et al. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep. 2016;6:38180.
Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics. 2011;10:M110.004945.
Tan Y, Yin P, Tang L, et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics. 2012;11:M111.010694.
Riboli E, Kaaks R. The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol. 1997;26:S6-S14.
García-Cañaveras JC, Donato MT, Castell JV, Lahoz A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res. 2012;53:2231-2241.
Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059-1062.
Luo L, Aubrecht J, Li D, et al. Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PLoS One. 2018;13:e0193824.
Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41-50.
Ikegami T, Honda A. Reciprocal interactions between bile acids and gut microbiota in human liver diseases. Hepatol Res. 2018;48:15-27.
Guizoni DM, Vettorazzi JF, Carneiro EM, Davel AP. Modulation of endothelium-derived nitric oxide production and activity by taurine and taurine-conjugated bile acids. Nitric Oxide. 2020;94:48-53.
Wang J, Wang Y, Zhang X, et al. Gut microbial Dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol. 2017;8:2222.
Inoue T, Nakayama J, Moriya K, et al. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis. 2018;67:869-877.
Fedirko V, Tran HQ, Gewirtz AT, et al. Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study. BMC Med. 2017;15:72.
Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science (New York, NY). 2018;360:360.
Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103-117.
Sang C, Wang X, Zhou K, et al. Bile acid profiles are distinct among patients with different etiologies of chronic liver disease. J Proteome Res. 2021;20:2340-2351.